0000902664-21-004071.txt : 20210830 0000902664-21-004071.hdr.sgml : 20210830 20210830193923 ACCESSION NUMBER: 0000902664-21-004071 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210826 FILED AS OF DATE: 20210830 DATE AS OF CHANGE: 20210830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Avoro Capital Advisors LLC CENTRAL INDEX KEY: 0001633313 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38560 FILM NUMBER: 211225040 BUSINESS ADDRESS: STREET 1: 110 GREENE STREET STREET 2: SUITE 800 CITY: NEW YORK STATE: NY ZIP: 10012 BUSINESS PHONE: 212-937-4975 MAIL ADDRESS: STREET 1: 110 GREENE STREET STREET 2: SUITE 800 CITY: NEW YORK STATE: NY ZIP: 10012 FORMER NAME: FORMER CONFORMED NAME: venBio Select Advisor LLC DATE OF NAME CHANGE: 20150210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Avoro Ventures LLC CENTRAL INDEX KEY: 0001879253 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38560 FILM NUMBER: 211225039 BUSINESS ADDRESS: STREET 1: 110 GREEN STREET, SUITE 800 CITY: NEW YORK STATE: NY ZIP: 10012 BUSINESS PHONE: (212) 937-4975 MAIL ADDRESS: STREET 1: 110 GREEN STREET, SUITE 800 CITY: NEW YORK STATE: NY ZIP: 10012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aghazadeh Behzad CENTRAL INDEX KEY: 0001701815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38560 FILM NUMBER: 211225041 MAIL ADDRESS: STREET 1: C/O AVORO CAPITAL ADVISORS LLC STREET 2: 110 GREENE STREET, SUITE 800 CITY: NEW YORK STATE: NY ZIP: 10012 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aadi Bioscience, Inc. CENTRAL INDEX KEY: 0001422142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 BUSINESS PHONE: 424-473-8055 MAIL ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 FORMER COMPANY: FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20170316 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP II DATE OF NAME CHANGE: 20071227 4 1 ownership.xml X0306 4 2021-08-26 0 0001422142 Aadi Bioscience, Inc. AADI 0001701815 Aghazadeh Behzad C/O AVORO CAPITAL ADVISORS LLC 110 GREENE STREET, SUITE 800 NEW YORK NY 10012 1 0 1 1 See Remarks 0001633313 Avoro Capital Advisors LLC 110 GREENE STREET SUITE 800 NEW YORK NY 10012 1 0 0 1 See Remarks 0001879253 Avoro Ventures LLC 110 GREENE STREET, SUITE 800 NEW YORK NY 10012 0 0 0 1 See Remarks Common Stock, $0.0001 par value per share ("Common Stock") 2021-08-26 4 A 0 1911752 13.077 A 2211752 I See footnotes Stock option (right to buy) 26.00 2021-08-27 4 A 0 17549 0.00 A 2031-08-27 Common Stock 17549 17549 D This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures directly from the Issuer in a PIPE financing completed in connection with the closing of the Agreement and Plan of Merger between the Issuer and Aadi Bioscience, Inc., dated as of May 16, 2021, following which the Issuer changed its name to Aadi Bioscience, Inc. In connection with the closing of the Merger, as approved by the stockholders of the Issuer on August 17, 2021, the Board granted on August 26, 2021 to the Reporting Person an Initial Award (as defined in the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan")). Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021. Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer. Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer 2021-08-30 Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Financial Officer 2021-08-30 /s/ Behzad Aghazadeh 2021-08-30